Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment
Cancers · 24.08.2023 · 15 (17) · 4234
DOI: 10.3390/cancers15174234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 24.08.2023. Verfasst von Yosuke Tamura und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda (Japan), Bristol-Myers Squibb, MSD K.K., Bristol-Meyers Squibb, Gilead Sciences.
Abstract (Originalsprache)
It has been reported that high intensity in the hepatobiliary (HB) phase of Gd-EOB-DTPA-enhanced MRI (EOB-MRI) is associated with an immune-cold microenvironment in HCC. The aim of this study is to reveal whether non-high-intensity HCCs are homogeneous with respect to the immune microenvironment and to investigate the predictive ability of EOB-MRI for the response to atezolizumab + bevacizumab therapy (Atezo/Bev). The association between differences in stepwise signal intensity of HB phase and molecular subtypes and somatic mutations associated with the immune microenvironment was investigated in 65 HCC patients (cohort 1). The association between EOB-MRI and the therapeutic effect of Atezo/Bev was evaluated in the Atezo/Bev cohort (60 patients in cohort 2). The proportion of HCCs having CTNNB1 mutations and classified as Chiang CTNNB1 and Hoshida S3 was high in the high-intensity HB-phase group. Infiltration of tumor-associated macrophages (TAM) and regulatory T-lymphocytes (Treg) was characteristic of the high-intensity and low-intensity groups, respectively. Although EOB-MRI could not predict the response to Atezo/Bev treatment, our results demonstrate that EOB-MRI could serve as a surrogate marker predicting the immune microenvironment. This suggests that Atezo/Bev treatment can be selected regardless of signal intensity in the EOB-MRI HB phase.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
- Cancer Treatment Center, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
- Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
- Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
- Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
- Collaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
ORCID-Profile: Atsushi Ono, Shinsuke Uchikawa, Masataka Tsuge, Masahiro Serikawa, Tsuyoshi Kobayashi, Hidewaki Nakagawa, Hiroshi Aikata
Förderung
- Takeda (Japan)
- Bristol-Myers Squibb
- MSD K.K., Bristol-Meyers Squibb, Gilead Sciences
- Dainippon Sumitomo Pharma
- Canon Medical Systems
- Takeda Science Foundation
Zitieren
APA
Tamura, Y., Ono, A., Nakahara, H., Hayes, C. N., Fujii, Y., Zhang, P., Yamauchi, M., Uchikawa, S., Teraoka, Y., Uchida, T., Fujino, H., Nakahara, T., Murakami, E., Tsuge, M., Serikawa, M., Miki, D., Kawaoka, T., Okamoto, W., Imamura, M., …, & Oka, S. (2023). Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment. Cancers, 15(17), 4234. https://doi.org/10.3390/cancers15174234
Vancouver
Tamura Y, Ono A, Nakahara H, Hayes CN, Fujii Y, Zhang P, et al. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment. Cancers. 2023;15(17):4234. doi:10.3390/cancers15174234
BibTeX
@article{Tamura2023,
author = {Tamura, Yosuke and Ono, Atsushi and Nakahara, Hikaru and Hayes, Clair Nelson and Fujii, Yasutoshi and Zhang, Peiyi and Yamauchi, Masami and Uchikawa, Shinsuke and Teraoka, Yuji and Uchida, Takuro and Fujino, Hatsue and Nakahara, Takashi and Murakami, Eisuke and Tsuge, Masataka and Serikawa, Masahiro and Miki, Daiki and Kawaoka, Tomokazu and Okamoto, Wataru and Imamura, Michio and Nakamura, Yuko and Awai, Kazuo and Kobayashi, Tsuyoshi and Ohdan, Hideki and Fujita, Masashi and Nakagawa, Hidewaki and Chayama, Kazuaki and Aikata, Hiroshi and Oka, Shiro},
title = {Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment},
journal = {Cancers},
year = {2023},
volume = {15},
number = {17},
pages = {4234},
doi = {10.3390/cancers15174234}
}
EUVIMED